Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Retained Earnings data on file, last reported at -$384.2 million in Q1 2026.

• Quarterly Retained Earnings fell 468400.0% year-over-year to -$384.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$384.2 million (down 468400.0% YoY) and the FY2025 annual result came in at -$422.1 million, down 66987.48% from the prior year.
• Retained Earnings advanced to -$384.2 million in Q1 2026, from -$422.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $631000.0 in Q4 2024 to a low of -$469.6 million in Q3 2024.
• A 5-year average of -$268.2 million and a median of -$346.1 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.16% — and 2026, when it plunged 468400.0%.
• Tracing ZVRA's Retained Earnings over 5 years: stood at -$353.7 million in 2022, then slipped by 13.02% to -$399.8 million in 2023, then jumped by 100.16% to $631000.0 in 2024, then sank by 66987.48% to -$422.1 million in 2025, then grew by 8.98% to -$384.2 million in 2026.
• The last three Retained Earnings figures came in at -$384.2 million (Q1 2026), -$422.1 million (Q4 2025), and -$434.2 million (Q3 2025), per Business Quant data.